Neoplasms – Page 5

Zanidatamab Demonstrates Promising 30-Month Survival Rate in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma

7 months ago talkbio0Tagged Antibodies, Bispecific, HER2-positive, Malignant neoplasm of stomach, Metastatic gastroesophageal adenocarcinoma, Neoplasms, Survival Rate, Zanidatamab

Zanidatamab, HER2-positive, metastatic gastroesophageal adenocarcinoma, bispecific antibody, survival rate, gastric cancer, oncology.

AstraZeneca Unveils In-House ADCs, Rivaling AbbVie and Pfizer’s Cancer Therapies

7 months ago talkbio0Tagged AbbVie, Antibody-Drug, Antibody-Drug Conjugates, AstraZeneca, Biotechnology, Daiichi, Immunostimulating conjugate (antigen), Neoplasms, Pfizer, Sankyo

AstraZeneca, Daiichi Sankyo, Antibody-Drug Conjugates (ADCs), Cancer Therapies, AbbVie, Pfizer, Oncology, Biotechnology

Sanofi Enters Radiopharmaceutical Market with $110M Licensing Deal for AlphaMedix, Challenging Novartis’ Dominance

7 months ago talkbio0Tagged AlphaMedix, Cancer Therapeutic Procedure, Drug Industry, Neoplasms, Neurosecretory Systems, Novartis, radioligand therapy, Radiopharmaceuticals, sanofi

Sanofi, radiopharmaceuticals, radioligand therapy, AlphaMedix, Novartis, neuroendocrine tumors, cancer treatment, pharmaceutical industry

Sanofi Enters Radiopharmaceutical Market with $110 Million Licensing Agreement

7 months ago talkbio0Tagged AlphaMedix, Multiple Epiphyseal Dysplasia, Neoplasms, Neurosecretory Systems, RadioMedix, Radiopharmaceuticals, sanofi

Sanofi, Radiopharmaceuticals, Licensing Deal, RadioMedix, Orano Med, AlphaMedix, Neuroendocrine Tumors

Bayer and NextRNA Therapeutics Collaborate on $547 Million Deal to Develop Innovative Cancer Therapies Targeting Long Non-Coding RNAs

8 months ago talkbio0Tagged Bayer, Drug Development, Long Intergenic Non-Protein Coding RNA, Neoplasms, NextRNA, Partnership

Bayer, NextRNA Therapeutics, lncRNA, small molecules, cancer, oncology, partnership, drug development

FDA Approves Illumina’s TruSight Oncology Comprehensive Test for Pan-Cancer Companion Diagnostics

8 months ago talkbio0Tagged Approved, cellular targeting, Comprehensive, Diagnostics, Gene Fusion, Illumina, Neoplasms, NTRK, pan-cancer, Pet Animal, Precision - temporal, RET protein, human, TruSight Oncology, United States Food and Drug Administration

FDA approval, Illumina, TruSight Oncology Comprehensive, pan-cancer, companion diagnostics, NTRK gene fusions, RET fusion-positive NSCLC, targeted therapies, precision oncology.

Merck & Co., Daiichi Sankyo Strengthen Partnership with New DLL3 Cancer Drug Agreement

9 months ago talkbio0Tagged Antibody-Drug, Daiichi, DLL3, DLL3 gene, Immunostimulating conjugate (antigen), Merck & Co., MK-6070, Neoplasms, Neurosecretory Systems, Oncology Pipeline, Sankyo, Small cell carcinoma of lung, T-Lymphocyte

Merck & Co., Daiichi Sankyo, DLL3, T-cell engager, MK-6070, small cell lung cancer, neuroendocrine tumors, antibody-drug conjugates, oncology pipeline

Eisai Partners with SEED Therapeutics for $1.5 Billion Biobucks Deal in Neurodegeneration and Oncology

9 months ago talkbio0Tagged biobucks, Eisai, molecular glue degraders, Neoplasms, Nerve Degeneration, Plant seeds

Eisai, SEED Therapeutics, biobucks deal, neurodegeneration, oncology, molecular glue degraders

Impact of Padcev/Keytruda Momentum on US Sales of Merck KGaA’s Bavencio in Bladder Cancer

9 months ago talkbio0Tagged Bavencio, Keytruda, Malignant neoplasm of urinary bladder, Merck KGaA, Neoplasms, Padcev, Sales - occupational activity

Merck KGaA, Bavencio, Padcev, Keytruda, bladder cancer, US sales, pharmaceuticals, oncology

FibroGen Lays Off 75% of US Staff After Cancer Drug Fails in Two Phase III Trials

9 months ago talkbio0Tagged Anemia, Antineoplastic Agents, Astellas, AstraZeneca, FibroGen, Neoplasms, pamrevlumab, Pancreatic carcinoma, Pharmacotherapy, Phase 3 Clinical Trials, roxadustat

FibroGen, cancer drug, layoffs, Phase III trials, pamrevlumab, oncology, pancreatic cancer, chemotherapy, anaemia therapy, roxadustat, Astellas, AstraZeneca